Summary
This prediction ended on 27.06.20 with a price of €24.04. With a performance of 2.91%, the BUY prediction by Traumtanz for Evotec SE closed with a slight gain. Traumtanz has a follow-up prediction for Evotec SE where he still thinks Evotec SE is a Buy. Traumtanz has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | 9.016% | 9.016% | -18.506% | -56.674% |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% | 16.854% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% | 42.934% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% | 2.941% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% | 41.955% |
According to Traumtanz what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Well known brand
Higher EBIT margin than peer group
Top Rating
Valuable balance sheet
Innovative
Stable Large shareholder and/or long term investor
Medium risks for its business
Fair valuation
High dividend yield expected
positive Cash Flow expected
High Investments for future growth
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Good culture
Some uniques
Very differentiated customer and product portfolio
Growths faster than the competition
Sustainability is very important
Market Leader or Top 3
Small cyclical dependencies
Very Future proof/growth oriented business model
Capable Management
Cons
Comments by Traumtanz for this prediction
In the thread Evotec AG diskutieren
Kursziel gesetzt auf 30,0